EPO
Labeled ESA biologics (epoetin/darbepoetin class) — anemia labels; Besarab/CHOIR/CREATE/TREAT harm visible; ≠ ARA-290.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Erythropoietin (EPO) is an endogenous glycoprotein hormone; therapeutic objects are recombinant erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa (and related biosimilars/analogues). No clean small-molecule PubChem CID is used here (protein biologic; name-search collisions exist). Labeled anemia indications (CKD, chemotherapy-associated anemia, selected other settings — jurisdiction-specific labels) are separate from gray-market “EPO peptide” / performance-enhancement talk. ≠ ARA-290 / cibinetide (non-erythropoietic EPO-derived peptide — separate drawer). This drawer marks educational papers on labeled ESA objects. It is not use advice.
Bottom line
Large RCTs show ESAs raise hemoglobin in CKD anemia but higher hemoglobin targets increased harm in landmark trials (Normal Hematocrit / Besarab; CHOIR; CREATE; TREAT). Network meta-analyses compare ESA options for CKD anemia. Separate labeled anemia evidence from any unregulated peptide-vial narrative. Refuse athletic “blood doping” framing as education for use.
Papers
Landmark ESA target / outcome RCTs (labeled anemia objects)
PMID 9718377 — Besarab 1998
Tested: normal vs low hematocrit targets with epoetin in hemodialysis patients with cardiac disease (Normal Hematocrit Cardiac Trial).
Does not show: that higher hematocrit targets are safe; study halted with more primary events in the normal-hematocrit arm — harm signal, not a green light for aggressive ESA use.
PMID 17108343 — Singh 2006 (CHOIR)
Tested: correction of anemia with epoetin alfa in CKD (higher vs lower hemoglobin target).
Does not show: benefit for higher targets; associated with increased risk of composite events.
PMID 17108342 — Drüeke 2006 (CREATE)
Tested: normalization of hemoglobin in CKD anemia with early epoetin treatment.
Does not show: cardiovascular benefit from normalizing hemoglobin.
PMID 19880844 — Pfeffer 2009 (TREAT)
Tested: darbepoetin alfa in type 2 diabetes and CKD anemia.
Does not show: stroke-safe hemoglobin raising for all targets; notable stroke signal in the treated strategy.
Evidence synthesis / comparative ESA context
PMID 36791280 — Chung 2023
Tested: network meta-analysis of erythropoiesis-stimulating agents for anaemia in adults with CKD.
Does not show: endorsement of gray-market EPO; synthesizes regulated ESA evidence.
PMID 39038479 — Della Porta 2024
Tested: luspatercept versus epoetin alfa in ESA-naive transfusion-dependent lower-risk MDS (COMMANDS).
Does not show: that MDS trial objects equal athletic or anti-aging EPO use; different labeled population.
PMID 35361724 — Fishbane 2022
Tested: roxadustat versus epoetin alfa for anemia in dialysis CKD (ROCKIES Phase 3 framing — HIF-PHI comparator context).
Does not show: gray-market peptide equivalence; keeps ESA as the labeled biologic comparator object.
What is not established
Safety or legitimacy of unlabeled “EPO peptide” products for performance or wellness. That ARA-290 papers are EPO anemia evidence. That higher hemoglobin targets are desirable (landmark trials argue caution). Any education herein as a protocol for self-administration. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
9718377 17108343 17108342 19880844 36791280 39038479 35361724
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.